Novartis stock slips after neutral analyst stance but Q2 growth story stays intact

Novartis AG (CH0012005267) stock is trading modestly lower on August 24, 2026, as shares on the SIX Swiss Exchange hover around 126.80 CHF with a loss of about half a percent compared with the previous session, while the broader Swiss Market Index shows a smaller decline.

The move comes against the backdrop of second quarter 2026 results that showed net sales rising to $14.4 billion and core earnings per share improving to $2.41, supported by strong demand for oncology therapies including a double digit growth rate for Pluvicto.

For investors, the key tension now lies between the softer trading day and management's reiterated confidence that sales should return to growth in the second half of 2026 and that the group can sustain a solid medium term expansion profile despite upcoming patent expiries.

Q2 2026 earnings underline growth momentum

In its most recent reported period, the second quarter of 2026, Novartis delivered net sales of $14.4 billion, a figure that marked an increase compared with the prior year quarter and underlined the group's ability to grow its top line even as generic competition builds in several franchises.

Quarterly core earnings per share reached $2.41 in Q2 2026, reflecting both higher sales and efficiency gains in the cost base, and giving Novartis more room to keep investing in late stage drug development while returning capital through its ongoing share repurchase program.

Within oncology, Novartis highlighted a 43 percent constant currency jump in sales for Pluvicto in the second quarter of 2026, a standout performance that shows how radioligand therapies are becoming an increasingly important pillar of the company's growth story and that helps offset slower trends in some more mature cancer medicines.

Analyst stance and stock performance on August 24, 2026

On August 24, 2026, Novartis shares are among the weaker names in the Swiss Market Index, with the stock quoted around 126.80 CHF and intraday data showing a decline of 0.49 percent compared with the previous closing level, while the benchmark index is down by a smaller margin.

Trading ranges during the session have seen the Novartis share price move between intraday levels near 126.20 CHF and an opening print close to 126.94 CHF, indicating a relatively tight range but confirming that the pressure is skewed to the downside for the day.

Market data compiled on August 24, 2026 also point to the fact that Novartis stock has gained 15.35 percent since the start of 2026, while the five day change stands at a positive 2.45 percent, suggesting that the current softness is taking place against a backdrop of a broadly constructive year to date performance.

Medium term outlook and sales guidance

Recent meetings between Novartis management and investors have reinforced the message that the company expects group sales to return to growth in the second half of 2026, a key guidance point that anchors expectations for both the core pharmaceutical portfolio and newer launches.

The medium term outlook set out in these discussions stresses that, despite patent losses expected through 2030 in some legacy products, Novartis aims to maintain a healthy growth profile through a combination of innovative oncology assets, immunology drugs and cardiovascular therapies.

This narrative is important for valuation because it helps explain why the average target price compiled for the Novartis stock is 154.23 USD for the share traded in New York, compared with a latest closing price of 158.98 USD for the United States listing, implying that consensus sees limited near term upside but still recognizes the company's strategic strengths.

Technical context for Novartis shares

From a technical perspective, the current level around 126.80 CHF on August 24, 2026 leaves Novartis shares below recent intraday highs but comfortably above longer term lows, with the session's decline of 0.49 percent contrasting with the Swiss Market Index's 0.19 percent loss at similar timestamps.

The fact that the year to date performance stands at a gain of 15.35 percent, compared with much smaller moves for some defensive healthcare peers, indicates that Novartis stock has already priced in a significant part of the expected earnings recovery, which can limit the scope for immediate rerating in response to incremental positive news.

On the other hand, the five day increase of 2.45 percent shows that short term momentum remains positive, so a neutral analyst recommendation combined with modest daily volatility may simply represent a consolidation phase rather than the start of a deeper reversal in the trend.

Pluvicto as a representative growth product

Among Novartis's key products, the radioligand therapy Pluvicto has emerged as a flagship example of how the company's oncology franchise is changing, with second quarter 2026 sales growing 43 percent in constant currency compared with the prior year period.

Pluvicto is used to target specific cancer cells through precision delivery of radiation, and the strong growth rate reported for Q2 2026 suggests expanding adoption in both initial treatment settings and in lines of therapy where patients have limited options, reinforcing the product's strategic importance.

For Novartis, such double digit expansion in a single branded medicine provides a concrete counterweight to revenue erosion in off patent segments and helps support the broader narrative that innovation can sustain overall sales even as generic pressures remain a structural feature of the pharmaceutical landscape.

Novartis stock and trading venue

Novartis shares primarily trade on the SIX Swiss Exchange, and the August 24, 2026 session shows the stock quoted around 126.80 CHF with an intraday decline of 0.49 percent, while the broader Swiss Market Index prints levels near 14,427.75 at timestamps within the same trading window.

In addition to the Swiss listing, Novartis stock is also represented in the United States as NVS, where the latest closing price stands at 158.98 USD and consensus targets are collated at 154.23 USD, providing investors with a cross market perspective on valuation and currency adjusted returns.

Read more

Go deeper on Novartis's latest strategy and earnings presentation via the company's investor relations resources and recent coverage that detail the Q2 2026 performance and management's second half outlook.

Investor Relations

More on Novartis stock

Fact box

Company: Novartis AG

ISIN: CH0012005267

Ticker: NOVN

Exchange: SIX Swiss Exchange

Price (as of August 24, 2026): 126.80 CHF

Market cap: data as of the latest available session

Sector / Industry: Health Care / Pharmaceuticals

Index membership: Swiss Market Index